

**PFIZER INC.**

This document is provided pursuant to Regulation (EC) No 1901/2006 and Communication (2009/C 28/01)

**PROPRIETARY DRUG NAME®/GENERIC DRUG NAME:**

CP-751871

**PROTOCOL NO.:**

A4021017

**EudraCT NUMBER:**

2008-004008-30

**PROTOCOL TITLE:**

Randomized, Open Label, Phase 3 Clinical Study to Evaluate the Effect of the Addition of CP-751,871 to Gemcitabine and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer

**Study Centers**

Data not available

**Study Initiation and Final Completion Dates**

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.

**Phase of Development:**

Phase 3

**Study Objectives:**

Gemcitabine and cisplatin given together is a standard treatment option for advanced lung cancer patients. The purpose of this study is to assess if the life span is longer in patients taking the investigational drug CP-751,871 in combination with gemcitabine and cisplatin compared to gemcitabine and cisplatin alone. Considering a 10% rate of drop-outs, 1,210 participants will be required in order to have an adequate sample size (1,100 evaluable patients) and power to detect a 30% prolongation of survival on the experimental arm.

**METHODS**

Data not available

## **RESULTS**

### **Subject Disposition and Demography:**

Data not available

### **Efficacy Results:**

Data not available

### **Safety Results:**

Data not available

## **CONCLUSION:**

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.